PT  - JOURNAL ARTICLE
AU  - Baberwal, Parth
AU  - Parghane, Rahul
AU  - Basu, Sandip
TI  - Identification of Wandering Masses and Tumor Heterogeneity on <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT
AID  - 10.2967/jnmt.123.267286
DP  - 2024 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - 272--273
VI  - 52
IP  - 3
4099  - http://tech.snmjournals.org/content/52/3/272.short
4100  - http://tech.snmjournals.org/content/52/3/272.full
SO  - J. Nucl. Med. Technol.2024 Sep 01; 52
AB  - Neuroendocrine tumors (NETs) may manifest as large masses in the abdominopelvic region that exhibit mobility and shifting, potentially leading to diagnostic uncertainty both before and after treatment. A meticulous analysis of PET/CT scans is advantageous in accurately identifying the precise location of large abdominopelvic masses. Tumor heterogeneity may be present in NETs with large abdominopelvic masses and may be easily identified on dual-tracer (68Ga-DOTATATE and 18F-FDG) PET/CT scans. In this scenario, the combined use of chemotherapy and peptide receptor radionuclide therapy is a more effective treatment option than monotherapy. Here, we present a case of a NET with wandering, large, heterogeneous masses in the abdominopelvic regions that were identified using dual-tracer PET/CT. After the administration of temozolomide chemotherapy in a combined chemotherapy–peptide receptor radionuclide therapy approach, we observed an upregulation in the expression of somatostatin receptor in the abdominopelvic masses.